News | May 04, 2010

Cardiac Device Identifies Patients At Risk of Heart Failure Hospitalizations

May 4, 2010 — New research released this week in the Journal of the American College of Cardiology shows the value of implantable cardiac device diagnostics in identifying worsening heart failure.

The combined use of two Medtronic's diagnostic OptiVol Fluid Status Monitoring and Cardiac Compass trends can identify patients with a 5.5 times greater risk for a heart failure (HF) hospitalization with pulmonary congestion within the next month, according to findings from the PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) trial.

PARTNERS HF is a prospective, observational, post-market study designed to demonstrate the value of using HF device diagnostic information to risk stratify patients.

Heart failure affects nearly 5 million Americans and related hospitalizations cost $18.8 billion annually in the United States. Heart failure patients may be candidates for cardiac resynchronization therapy-defibrillators (CRT-Ds), implantable devices that help the heart pump normally. These CRT-Ds may also include the OptiVol and Cardiac Compass diagnostic tools to help monitor symptoms in these patients.

About 1,024 CRT-D patients from 100 U.S. centers were enrolled in the PARTNERS HF study. Patients were nonrandomized and followed for 12 months.

“These findings demonstrate that routine monitoring with tools like OptiVol and Cardiac Compass can help me identify patients who are at risk for a future hospitalization,” said David Whellan, M.D., MHS, associate professor of medicine, Thomas Jefferson University Hospital in Philadelphia. “Monitoring device diagnostics every 30 days allows providers to risk stratify their patients and better identify those who should be monitored more closely.”

Traditional methods of assessing physical signs or symptoms to evaluate and predict heart failure events is only done intermittently and, consequently, may not identify patients in time to prevent imminent adverse events. While prior studies have demonstrated the ability of individual pieces of heart failure device diagnostic data to predict heart failure events, PARTNERS HF suggests that a combination of heart failure device diagnostics in a single algorithm improves the overall ability to identify those heart failure patients at the greatest risk of hospitalization.

For more information:

Related Content

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
This is a brief overview of updates on...
Emblem Subcutaneous ICD Safe and Effective for Majority of Patients
News | Implantable Cardioverter Defibrillator (ICD) | May 13, 2019
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of t
Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Overlay Init